presid



Applicant:

Jingrong Jean CUI et al.

Title:

AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE

INHIBITORS

Appl. No.:

10/786,610

Filing Date: 02/26/2004

Examiner:

Unassigned

Art Unit:

1614

INFORMATION DISCLOSURE STATEMENT **UNDER 37 CFR §1.56**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98. Copies of documents B2 – B10 are being submitted herewith on a CD-R. Paper copies of documents B1 and B11 – B18 are submitted herewith.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a prima facie art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date

FOLEY & LARDNER LLP

Customer Number: 22428

Telephone: Facsimile:

(202) 672-5475

(202) 672-5399

Beth A. Burrous

Attorney for Applicant

Registration No. 35,087

MODIFIED PTO/SB/08 (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute for	or form 1449B	/PTO		Complete if Known	OIPE	
	INFORMATI	ON DISCLO	SURE	Application Number	10/786,610	7	
	STATEMEN	T BY APPL	ICANT	Filing Date	02/26/2004	- C	
				First Named Inventor	Jingrong Jean CUI	SEP 2 9 2004	
				Group Art Unit	1614	1	
	(use as many :	sheets as ne	ecessary)	Examiner Name	Unassigned	E .	
Sheet	1	of	2	Attorney Docket Number	034536-1148	E ALONA 34 CI	

				F	DREIGN PATENT DOCUMENT	S		
Examiner Initials*	Cite No. ¹	Office	oreign Patent Do	cument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Te
	B1	JP	07-109260	А	FUJI PHOTO FILM CO LTD	04-25-1995		
	B2	EP	0 204 285	B1	FUJISAWA PHARMACEUTICAL CO., LTD.	01-15-1992		
	В3	EP	1 044 967	B1	PFIZER INC. & PFIZER LIMITED	08-11-2004		
	B4	wo	93/15055	A1	SMITHKLINE BEECHAM INTERCREDIT B.V.	08-05-1993		
	B5	wo	99/55706	A1	ASTRA AKTIEBOLAG	11-04-1999		
	В6	wo	01/00213	A1	MERCK & CO., INC.	01-04-2001		
	B7	wo	01/60806	A2	NEUROGEN CORPORATION	08-23-2001		
	B8	wo	02/056882	A1	SMITHKLINE BEECHAM P.L.C.	07-25-2002		
	B9	wo	03/000666	A1	PFIZER PRODUCTS INC.	01-03-2003		
	B10	wo	03/045924	A1	PHARMACIA & UPJOHN COMPANY	06-05-2003		

	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.							
	B11	BRADBURY et al., "New Non-Peptide Endothelin-A Receptor Antagonists: Synthesis, Biological Properties, and Structure – Activity Relationships of 5-(Dimethylamino)- <i>N</i> -pyridyl-, - <i>N</i> -pyrimidinyl-, - <i>N</i> -pyridazinyl-, and – <i>N</i> -pyrazinyl-1-naphthalenesulfonamides," <u>J. Med. Chem.</u> , 1997, pp. 996-1004, Vol. 40, No. 6							
	B12	BRISTOL et al., "An Improved Synthesis of 2-Amino-3-alkyloxypyridines by a Phase-Transfer Catalyzed Ether Synthesis," Synthesis, December 1981, pp. 971-973, Vol. 12							

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute fo	or form 1449B	/PTO	Complete if Known		
	INFORMATI	ON DISCLO	SURE	Application Number	10/786,610	
	STATEMEN	T BY APPL	CANT	Filing Date	02/26/2004	
				First Named Inventor	Jingrong Jean CUI	
				Group Art Unit	1614	
	(use as many s	sheets as ne	cessary)	Examiner Name	Unassigned	
Sheet	2	of	2	Attorney Docket Number	034536-1148	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹						
	B13	DENNIN, et al., "Synthesis of Derivatives of Pyrazino[1,2-a]pyrimindin-4-ones," <u>Journal of Heterocyclic Chemistry</u> , September-October 1990, pp. 1639-1643, Vol. 27					
	B14	FOKS et al., "Studies on Pyrazine Derivatives. XXX. Sythesis of Pyrazinylamino-1,3-Diazacycloalkanes of Potential Circulatory Activity," Acta Poloniae Pharmaceutica, January/February 1997, pp. 55-62, Vol. 54, No. 1					
	B15	KAMINSKI et al., "Antiulcer Agents. 2. Gastric Antisecretory, Cytoprotective, and Metabolic Properties of Substituted Imidazo[1,2-a]pyridines and Analogues," <u>J. Med. Chem.</u> , 1987, pp. 2031-2046, Vol. 30					
	B16	SHIMOMURA et al., "Semi-synthetic aequorins with improved sensitivity to Ca ²⁺ ions," <u>Biochem. J.,</u> 1989, pp. 913-920, Vol. 261					
	B17	SOLLOGOUB et al., "First synthesis of 1-deazacytidine, the C-nucleoside analogue of cytidine," Tetrahedron Letters, 2001, pp. 3121-3123, Vol. 43					
	B18	WISTEROWICZ et al., Acta Poloniae Pharmaceutica, 1997, pp. 55-62, Vol. 54, No.1					

Examiner Signature	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.